Third party not-for-profit organizations promising independent, scientific and transparent drug value assessments are the newest voice in a national debate about drug prices. Insurers, pharmacy benefits managers and health systems are beginning to use these value assessments for structuring drug benefits and negotiating prices. Many drug manufacturers, however, are challenging what they consider a flawed methodology for product assessment and have recommended changes to the assessment frameworks.
Read Full Article »
